Does a drug do better when it is new?

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 470-473

  Fossati, R ^a   Confalonieri, C ^a   Apolone, G ^a   Cavuto, S ^a   Garattini, S ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Advanced breast cancer; Chemotherapy; Wish bias

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EPIDEMIOLOGY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMAN; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; HUMANS;

EID: 0036018914     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf053     Document Type: Article

References (42)

1. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31510 women
2. The wish bias
3. Results of long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: A reference
4. The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug
5. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer
6. Chemotherapy versus chemoimmunotherapy (CAF versus CAFVP versus CMF each plus or minus MER) for metastatic carcinoma of the breast: A CALGB study
7. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - A randomised study with more than 10 years follow-up from Cancer Cooperative Group (DBCG)
8. Combination chemotherapy of metastatic breast cancer: A randomized trial comparing the use of adriamycin to that of vinblastine
9. Response and survival in advanced breast cancer after two non-cross-resistant combinations
10. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy
11. Chemotherapy of advanced breast cancer: A randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)
12. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin
13. Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors
14. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer
15. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer
16. Combination chemotherapy and adriamycin in patients with advanced breast cancer
17. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study
18. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer
19. Comparison of induction chemotherapies for metastatic breast cancer
20. A comparison of intermittent versus continuous and of adriamycin versus methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study
21. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer
22. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma
23. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
24. Advanced breast cancer: A randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine
25. Weekly adriamycin versus 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial
26. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer
27. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma
28. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast
29. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer
30. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer
31. MMM (mitomycin/mitoxantrone/methotrexate): An effective new regimen in the treatment of metastatic breast cancer
32. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin
33. ICH Topic E10, Note for guidance on choice of control group in clinical trials
34. Historical and methodological developments in clinical trials at the National Cancer Institute
35. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer
36. Treatment of relapse of breast cancer after adjuvant systemic therapy - Review and guidelines for future research
37. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer
38. Evaluation of conflict of interest in economic analyses of new drugs used in oncology
39. Source of funding and outcome of clinical trials
40. Conflict of interest in the debate over calcium-channel antagonists
41. 'Evidence-based medicine and conflicts of interest'